Combined Methodologies for Determining In Vitro Bioavailability of Drugs and Prediction of In Vivo Bioequivalence From Pharmaceutical Oral Formulations

This research paper explores a novel combined methodology for predicting the in vitro bioavailability (BA) and in vivo bioequivalence (BE) of pharmaceutical oral formulations, specifically focusing on levonorgestrel (LVN) 1.5 mg generic and brand-name tablets. The study aimed to develop an in vitro model that could accurately assess drug release and gastrointestinal absorption, thereby reducing the need for extensive in vivo studies. The methodology integrated a standard dissolution test with an optimized parallel artificial membrane permeability assay (PAMPA). This combined approach revealed significant differences between the generic and brand-name LVN tablets. The generic tablet exhibited a notably lower release rate (15 ± 0.01 μg min−1) compared to the brand-name (30 ± 0.01 μg min−1), and reduced absorption (19 ± 7 × 10–6 cm/s Pe vs 41 ± 15 × 10–6 cm/s Pe). These findings were attributed to the presence of insoluble LVN/excipient aggregates in the dissolution media of the generic formulation, leading to non-superimposable dissolution profiles. The study concludes that this integrated dissolution-PAMPA method provides crucial insights into potential BE issues, offering a valuable tool for early-stage drug development and regulatory assessment of generic drugs.

This research paper explores a novel combined methodology for predicting the in vitro bioavailability (BA) and in vivo bioequivalence (BE) of pharmaceutical oral formulations, specifically focusing on levonorgestrel (LVN) 1.5 mg generic and brand-name tablets. The study aimed to develop an in vitro model that could accurately assess drug release and gastrointestinal absorption, thereby reducing the need for extensive in vivo studies. The methodology integrated a standard dissolution test with an optimized parallel artificial membrane permeability assay (PAMPA). This combined approach revealed significant differences between the generic and brand-name LVN tablets. The generic tablet exhibited a notably lower release rate (15 ± 0.01 μg min−1) compared to the brand-name (30 ± 0.01 μg min−1), and reduced absorption (19 ± 7 × 10–6 cm/s Pe vs 41 ± 15 × 10–6 cm/s Pe). These findings were attributed to the presence of insoluble LVN/excipient aggregates in the dissolution media of the generic formulation, leading to non-superimposable dissolution profiles. The study concludes that this integrated dissolution-PAMPA method provides crucial insights into potential BE issues, offering a valuable tool for early-stage drug development and regulatory assessment of generic drugs. Research Background and Significance The accurate evaluation of oral drug formulations’ bioavailability (BA) and bioequivalence (BE) is a cornerstone in pharmaceutical development and regulatory approval processes. Traditionally, BE assessments require extensive in vivo clinical studies, which are costly, time-consuming, and ethically challenging. Consequently, there is a critical need for reliable in vitro methodologies capable of predicting in vivo drug performance, thereby streamlining drug development and f